Potent and Safe
Active Immunotherapies
for a Cancer-Free Future

Scancell develops active immunotherapies for a cancer-free future by enhancing long-lasting tumour specific immunity. Our aim is to deliver safe, effective and patient-accessible therapies that are easy to administer in hard-to treat cancers.

Our Approach

Scancell is developing potent novel active immunotherapies from its proprietary platforms Immunobody^{^®} and Moditope^{^®} to transform cancer treatment for millions of patients.

Our lead product iSCIB1+, an Immunobody^{^®} DNA active immunotherapy, activates a strong and safe lasting immune response in patients with advanced melanoma, with the potential to set a new benchmark in the standard of care. The lead Moditope^{^®} peptide active immunotherapy has also shown encouraging Phase 2 data in a broad range of solid tumors.

View pipeline

Meet our leadership team

Our leadership team combines experienced and talented people who are committed to advancing our clinical programmes and translating innovative science for patient benefit.

Find out more